The case for & against
Bull & Bear analysis
Bullish
Amwell (NYSE: AMWL) is a prominent player in the telehealth sector, providing a platform that connects healthcare professionals with patients through digital means. The company focuses on enhancing healthcare accessibility, particularly through its subscription revenue model which accounts for nearly half of its total revenue. With a commitment to improve healthcare delivery, Amwell is well-positioned within the emerging trend of digitization in healthcare, particularly in remote and virtual care.
Bull says
- ↑Q2 revenue $52M hits high-end guidance; adjusted EBITDA loss shrinks to $1.2M
- ↑Raised FY 2026 revenue outlook to $200–205M on improving demand
- ↑Stock jumped ~25% post-earnings; cash position $196M with no debt
- ↑Subscription revenue now exceeds 50% of total, boosting recurring streams
- ↑Analysts lift price target to $12 and revise earnings forecasts upward
- ↑Book-to-price ~1.97 suggests undervaluation; strong institutional backing
Bear says
- ↓Total revenue down 26.6% YoY, signaling weak customer retention
- ↓Net loss of $9.6M in Q2 2026 highlights ongoing cash burn
- ↓Negative earnings yield and poor profitability metrics point to low returns
- ↓High stock volatility may trigger sharp price swings and investor anxiety
- ↓Negative momentum and liquidity factors reflect operational pressures
- ↓Small market cap and macro sensitivity limit financial resilience
Investment themes with AMWL
Demographics Elective Health + Family Care↓ -0.20%
Health services for families and elective treatments
HQY · DOCS · PRVA
Earnings Call · Q1 2024 · Mgmt. Guidance
Updated 05-04-2025bullish
Transcript signals
Bull points
- a vote of confidence in Converge.
- We believe we can see it enormously valuable and has a lot of potential for growth, adding a lot of value to members and creating a lot of savings and impact, clinical and financial, to the sponsors.
- We believe we can see it enormously valuable and has a lot of potential for growth, adding a lot of value to members and creating a lot of savings and impact, clinical and financial, to the sponsors.
Bear points
- the biggest change we're seeing is maybe from 2 or 3 years ago to today. And we think that many of those changes are permanent. What we've seen, first and foremost, is dramatic rise in sophistication of health systems. If telehealth was somewhat exciting and, in some cases, naive, today, hybrid care is a very effective tool that is known to do important things for health systems, to retain staff, to improve efficiency, to save time, to engage patients in a very meaningful way, to manage risk in a meaningful way, to name a few. So the RSPs that we see and the dialogue with health systems, both existing customers and new ones, is a very different dialogue than the one that we held only a couple of years ago.
- Payers typically, and Elevance is a good example of that, add virtual primary care.
- we estimate that has Change not happened, we would have been flat from a visit perspective year-over-year. So that cost us the volume decline that we saw in the first quarter here.
Read full transcript analysis ›